bristol-myers gets fda approval for devens cell therapy manufacturing facility.

bristol-myers squibb company (bmy) presents at jefferies healthcare conference (transcript).

bristol myers squibb (bmy) dips more than broader markets: what you should know. in the latest trading session bristol myers squibb (bmy) closed at $65.16 marking a -0.49% move from the previou

bristol-myers squibb company (bmy) presents at 2023 virtual asco investor event conference (transcript).

bristol-myers squibb weakness offers opportunity.

bristol myers (bmy) announces upbeat data from nsclc study. bristol myersbmy reported encouraging four-year follow-up results from its phase iii checkmate -9la study. this study evaluates the d

bristol myers opdivo/chemo shows durable results at four years in lung cancer patients. ) released four-year follow-up data from the phase 3 checkmate -9la trial to be presented in a late-breaking poster presentation at the 2023 american society of clin

obi pharma announces executive leadership management change – heidi wang ph.d. appointed as chief executive officer. dr. wang appointed by the obi pharma board of directors as chief executive officer to lead obi pharma with a vision and to bring innovat

biotech stock roundup: mrtx falls on study failure lxrx drug wins approval & more. the biotech sector has been in focus in the past week with key pipeline and regulatory updates. among these mi

3 top stocks that just went on sale. shares of walgreens boots alliance (nasdaq: wba) bristol myers squibb (nyse: bmy) and dominion energy (nyse: d) all recently saw 52-week lows.

bristol myers (bmy) lung cancer drug nda gets priority review. bristol myers squibb bmy announced that the fda accepted the new drug application (nda) for repotrectinib. the nda is seeking appr

high quality dividend growth near 52-week lows: bristol-myers squibb is a good bet.

bristol myers granted fda priority review for lung cancer therapy.

bristol myers squibb enters oversold territory (bmy). legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is

bristol-myers squibb receives positive chmp opinion recommending approval for opdivo with chemotherapy.

unusual put option trade in bristol-myers squibb (bmy) worth $520.00k. on may 25 2023 at 14:49:14 et an unusually large $520.00k block of put contracts in bristol-myers squibb (bmy) was sold with a strike price of $75.00 / s

bristol-myers squibb unusual options activity. a whale with a lot of money to spend has taken a noticeably ish stance on looking at options history for bristol-myers squibb (nyse:) we detected 10 strange trades. if we consider the specifics of each tra

bristol myers (bmy) reports pulmonary fibrosis study results. bristol myers squibb bmy announced encouraging results from a mid-stage study evaluating pipeline candidate bms-986278 in patients

looking into bristol-myers squibbs recent short interest. ) short percent of float has risen 4.94% since its last report. the company recently reported that it has

insiders selling zoom video communications bristol-myers squibb and this footwear manufacturer. the nasdaq closed lower on thursday after the fed increased rates by 25 basis points on wednesday. investors meanwhile focused on some notable insider trades.

bristol-myers squibb: attractive entry as new products sales accelerate.

bristol-myers squibbs breyanzi aces two lymphoma studies on overall response rate endpoint plus new collaboration. ) announced

bristol myers lianbios heart therapy camzyos gets ema panel nod.

bristol-myers (bmy) q1 earnings beat revlimid generics hurt sales. bristol-myers squibb company bmy reported mixed results for the first quarter of 2023. the company reported adjusted earnings per share of $2.05 which beat the zacks co

bristol myers squibb posts lower q1 sales as revlimid generic erosion bites chairman & ceo giovanni caforio to step down. ) said that its

bristol-myers squibb company non-gaap eps of $2.05 beats by $0.05 revenue of $11.3b misses by $290m.

bristol myers stock dips as q1 revenue falls amid generic impact on revlimid.

bristol myers squibb (bmy) surpasses q1 earnings estimates. bristol myers squibb (bmy) came out with quarterly earnings of $2.05 per share beating the zacks consensus estimate of $1.98 per share. this compares to earnings of $1.96 per

bristol myers looks to new ceo as competition from generic drugs heats up. bristol myers squibb said on wednesday evening its ceo giovanni caforio would step down in november and will be replaced by current chief commercialization officer chris

bristol-myers squibb affirms fy23 outlook. q1 adj. eps tops estimates. (rttnews) - while reporting financial results for the first quarter on thursday biopharmaceutical company bristol-myers squibb co. (bmy) affirmed its adjusted earnings and re